Table 3 Gastric cancer characteristics (N = 157)
Characteristics | |
|---|---|
ECOG status, n(%) | |
0 | 0 (0%) |
1 | 102 (65.0%) |
2 | 35 (22.3%) |
3 | 15 (9.6%) |
4 | 4 (2.5%) |
Missing | 1 (0.6%) |
Endoscopy results, n(%) | |
Penetrating | 111 (70.7%) |
Protruding | 15 (9.6%) |
Miscellaneous | 6 (3.8%) |
Superficial | 3 (1.9%) |
Linitis | 3 (1.9%) |
Not applicable | 15 (9.6%) |
Not done | 4 (2.5%) |
CT scan results, n(%) | |
Coeliac lymphadenopathy | 28 (17.8%) |
Liver metastasis | 19 (12.1%) |
Other metastasis (bone, lung, ovarian, etc.) | 69 (43.9%) |
No metastasis | 30 (19.1%) |
Missing | 11 (7.0%) |
Chest x-ray results, n(%) | |
Normal | 18 (11.5%) |
Central infiltration | 2 (1.3%) |
Other | 8 (5.1%) |
Missing | 129 (82.2%) |
Laboratory results, mean ± standard deviation | |
CA 19–9 (U/mL) | 1,122.00 ± 2,493.00 |
CEA (ng/ml) | 91.43 ± 419.01 |
Hemoglobin (g/dL) | 11.50 ± 2.20 |
Red blood cells count (10^12/L) | 4.19 ± 0.76 |
White blood cells count (10^9/L) | 7.30 ± 3.40 |
Platelets count (10^9/L) | 334.00 ± 254.00 |
Lymphocytes count (%) | 23.30 ± 12.90 |
Neutrophils count (%) | 58.00 ± 21.50 |
Abnormal results, n(%) | |
Hemoglobin | 73 (46.5%) |
Red blood cells | 48 (30.6%) |
Lymphocytes | 29 (18.5%) |
Neutrophils | 26 (16.6%) |
White blood cells | 25 (15.9%) |
Monocytes | 19 (12.1%) |
CA | 14 (8.9%) |
Eosinophils | 14 (8.9%) |
CEA | 9 (5.7%) |
Vitamin B12 | 6 (3.8%) |
Basophils | 5 (3.2%) |
Gastric cancer stage, n(%) | |
IA | 3 (1.9%) |
IB | 2 (1.3%) |
II | 33 (21.0%) |
IIIA | 12 (7.6%) |
IIIB | 19 (12.1%) |
IV | 76 (48.4%) |
Not applicable | 12 (7.6%) |
Sites of metastases, n(%) | |
Bone | 5 (3.2%) |
Brain | 1 (0.6%) |
Liver | 25 (15.9%) |
Lung | 5 (3.2%) |
NA | 2 (1.3%) |
No metastasis | 79 (50.3%) |
Other | 40 (25.5%) |
Histology results, n(%) | |
Hepatoid adenocarcinoma | 1 (0.6%) |
Mucinous adenocarcinoma | 7 (4.5%) |
Other | 19 (11.5%) |
Papillary adenocarcinoma | 3 (1.9%) |
Signet-ring cell carcinoma | 34 (21.7%) |
Tubular adenocarcinoma, moderately differentiated | 44 (28.0%) |
Tubular adenocarcinoma, well differentiated | 11 (7.0%) |
Tubular adenocarcinoma, poorly differentiated | 38 (24.2%) |
Undifferentiated carcinoma | 1 (0.6%) |